Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Section 6 of 6

References

167 sources

  1. Abbey (2026) (opens in a new tab)
  2. Age-Related Eye Disease Study 2 Research Group (2013) (opens in a new tab)
  3. Age-Related Eye Disease Study Research Group (2001) (opens in a new tab)
  4. Ahluwalia et al. (2021) (opens in a new tab)
  5. American Academy of Ophthalmology IRIS63 measure specification (opens in a new tab)
  6. American Academy of Ophthalmology Medicare payment comparison (2026) (opens in a new tab)
  7. American Academy of Ophthalmology MIPS 2024 quality changes (2023) (opens in a new tab)
  8. Anegondi et al. (2025) (opens in a new tab)
  9. Annexon Biosciences ARCHER enrollment press release (2022) (opens in a new tab)
  10. Annexon Biosciences ARCHER II enrollment press release (2025) (opens in a new tab)
  11. Annexon Biosciences ARCHER II expansion press release (2026) (opens in a new tab)
  12. Annexon Biosciences ARCHER II registrational program press release (2023) (opens in a new tab)
  13. Annexon Biosciences ARCHER II update press release (2024) (opens in a new tab)
  14. Annexon Biosciences ARCHER initiation press release (2021) (opens in a new tab)
  15. Annexon Biosciences ARCHER topline press release (2023) (opens in a new tab)
  16. Annexon Biosciences ASRS 2023 press release (2023) (opens in a new tab)
  17. Annexon Biosciences Form 10-K (2021) (opens in a new tab)
  18. Annexon Biosciences Form 10-K (2026) (opens in a new tab)
  19. Annexon Biosciences Form 10-Q (2026) (opens in a new tab)
  20. Annexon Biosciences fourth-quarter 2024 results press release (2025) (opens in a new tab)
  21. Annexon Biosciences investor event presentation (2026) (opens in a new tab)
  22. Annexon Biosciences PDC pilot press release (2025) (opens in a new tab)
  23. Annexon Biosciences PRIME press release (2023) (opens in a new tab)
  24. Annexon Biosciences Retina Society press release (2026) (opens in a new tab)
  25. Annexon Biosciences second-quarter 2022 results press release (2022) (opens in a new tab)
  26. Annexon Biosciences third-quarter 2026 results press release (2026) (opens in a new tab)
  27. Annexon Biosciences vonaprument presentation (2026) (opens in a new tab)
  28. Apellis Pharmaceuticals Syfovre prescribing information (2025) (opens in a new tab)
  29. Astellas Pharma US Izervay prescribing information (2026) (opens in a new tab)
  30. Baker et al. (2026) (opens in a new tab)
  31. Bakri et al. (2023) (opens in a new tab)
  32. Bakri et al. (2024) (opens in a new tab)
  33. Barakat (2025) (opens in a new tab)
  34. Barakat (2026) (opens in a new tab)
  35. Bhavsar et al. (2026) (opens in a new tab)
  36. Borkar et al. (2025) (opens in a new tab)
  37. Borkar et al. (2026) (opens in a new tab)
  38. Boyer et al. (2017) (opens in a new tab)
  39. Boyer et al. (2024) (opens in a new tab)
  40. Brown et al. (2000) (opens in a new tab)
  41. Carlton et al. (2019) (opens in a new tab)
  42. Caswell et al. (2021) (opens in a new tab)
  43. Centers for Medicare & Medicaid Services Quality ID 14 (2023) (opens in a new tab)
  44. Chakravarthy (2026) (opens in a new tab)
  45. Chakravarthy et al. (2018) (opens in a new tab)
  46. Chakravarthy et al. (2024) (opens in a new tab)
  47. Chang (2026) (opens in a new tab)
  48. ClinicalTrials.gov NCT03488550 (opens in a new tab)
  49. ClinicalTrials.gov NCT04188015 (opens in a new tab)
  50. ClinicalTrials.gov NCT04656561 (opens in a new tab)
  51. ClinicalTrials.gov NCT04656561 results (opens in a new tab)
  52. ClinicalTrials.gov NCT06510816 (opens in a new tab)
  53. ClinicalTrials.gov NCT07807969 (opens in a new tab)
  54. CMS Medicare Part B Payment Limit File (2026) (opens in a new tab)
  55. CMS Medicare Part B Spending by Drug (2026) (opens in a new tab)
  56. CMS Medicare Quarterly Part B Spending by Drug (2026) (opens in a new tab)
  57. Colijn et al. (2017) (opens in a new tab)
  58. Csaky et al. (2024) (opens in a new tab)
  59. Cummings Joyner et al. (2023) (opens in a new tab)
  60. Danzig et al. (2024) (opens in a new tab)
  61. Dhoot et al. (2026) (opens in a new tab)
  62. Dinah et al. (2025) (opens in a new tab)
  63. Eichenbaum (2025) (opens in a new tab)
  64. Epshtein (2026) (opens in a new tab)
  65. Eriksen et al. (2025) (opens in a new tab)
  66. EU CTIS 2024-515022-88-00 (opens in a new tab)
  67. EURETINA Congress (2024) (opens in a new tab)
  68. European Medicines Agency Izelvay (2025) (opens in a new tab)
  69. European Medicines Agency Syfovre (2025) (opens in a new tab)
  70. Evans and Lawrenson (2023) (opens in a new tab)
  71. FDA De Novo DEN230083 (2024) (opens in a new tab)
  72. Fernández-Muro et al. (2026) (opens in a new tab)
  73. Fidler (2023) (opens in a new tab)
  74. Fleckenstein et al. (2021) (opens in a new tab)
  75. Fleckenstein et al. (2024) (opens in a new tab)
  76. Friedman et al. (2004) (opens in a new tab)
  77. Gallego-Pinazo (2026) (opens in a new tab)
  78. GBD 2021 Global AMD Collaborators (2025) (opens in a new tab)
  79. Goren Fein et al. (2026) (opens in a new tab)
  80. Grover et al. (2023) (opens in a new tab)
  81. Guymer et al. (2020) (opens in a new tab)
  82. Heier et al. (2020) (opens in a new tab)
  83. Heier et al. (2023) (opens in a new tab)
  84. Heier et al. (2024) (opens in a new tab)
  85. Holekamp et al. (2020) (opens in a new tab)
  86. Holz et al. (2014) (opens in a new tab)
  87. Hu et al. (2025) (opens in a new tab)
  88. Jackson et al. (2023) (opens in a new tab)
  89. Jaffe et al. (2021) (opens in a new tab)
  90. Jaffe et al. (2024a) (opens in a new tab)
  91. Jaffe et al. (2024b) (opens in a new tab)
  92. Jaffe et al. (2026) (opens in a new tab)
  93. Jiao et al. (2018) (opens in a new tab)
  94. Joachim et al. (2013) (opens in a new tab)
  95. Keenan et al. (2018) (opens in a new tab)
  96. Keenan et al. (2025) (opens in a new tab)
  97. Khanani et al. (2023) (opens in a new tab)
  98. Khanani et al. (2026) (opens in a new tab)
  99. Khurana (2025) (opens in a new tab)
  100. Khurana et al. (2024) (opens in a new tab)
  101. Kim et al. (2021) (opens in a new tab)
  102. Kimel et al. (2016) (opens in a new tab)
  103. Klein et al. (2008) (opens in a new tab)
  104. Krogh Nielsen et al. (2023) (opens in a new tab)
  105. Künzel et al. (2020) (opens in a new tab)
  106. Künzel et al. (2024) (opens in a new tab)
  107. Kuriyan et al. (2025) (opens in a new tab)
  108. Lad (2025) (opens in a new tab)
  109. Lad et al. (2024) (opens in a new tab)
  110. Lally (2025) (opens in a new tab)
  111. Legge (2024) (opens in a new tab)
  112. Li et al. (2020) (opens in a new tab)
  113. Li et al. (2026) (opens in a new tab)
  114. Lindblad et al. (2009) (opens in a new tab)
  115. Luo et al. (2026) (opens in a new tab)
  116. McGuinness et al. (2017) (opens in a new tab)
  117. Mitchell et al. (2018) (opens in a new tab)
  118. Morga et al. (2023) (opens in a new tab)
  119. National Institute for Health and Care Excellence pegcetacoplan appraisal (2026) (opens in a new tab)
  120. Patel et al. (2020) (opens in a new tab)
  121. Patel et al. (2024a) (opens in a new tab)
  122. Patel et al. (2024b) (opens in a new tab)
  123. Paudel et al. (2024) (opens in a new tab)
  124. Pearlman (2024) (opens in a new tab)
  125. Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026) (opens in a new tab)
  126. Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025) (opens in a new tab)
  127. Prasad et al. (2026) (opens in a new tab)
  128. Rahimy et al. (2023) (opens in a new tab)
  129. Regillo et al. (2024) (opens in a new tab)
  130. Rein et al. (2022a) (opens in a new tab)
  131. Rein et al. (2022b) (opens in a new tab)
  132. Rim et al. (2020) (opens in a new tab)
  133. Rowe et al. (2026) (opens in a new tab)
  134. Rudnicka et al. (2015) (opens in a new tab)
  135. Sadda et al. (2018) (opens in a new tab)
  136. Sambhara (2026) (opens in a new tab)
  137. Sarda et al. (2021) (opens in a new tab)
  138. Sarda et al. (2024) (opens in a new tab)
  139. Sarraf et al. (2026) (opens in a new tab)
  140. Saundankar et al. (2025a) (opens in a new tab)
  141. Saundankar et al. (2025b) (opens in a new tab)
  142. Schmitz-Valckenberg et al. (2016) (opens in a new tab)
  143. Sharma (2026) (opens in a new tab)
  144. Shen et al. (2018) (opens in a new tab)
  145. Shen et al. (2025) (opens in a new tab)
  146. Singh et al. (2023) (opens in a new tab)
  147. Stanga (2025) (opens in a new tab)
  148. Stanga et al. (2024) (opens in a new tab)
  149. Sun et al. (2023) (opens in a new tab)
  150. Sunness et al. (1997) (opens in a new tab)
  151. Sunness et al. (2007) (opens in a new tab)
  152. Sunness et al. (2008) (opens in a new tab)
  153. Tzoumas et al. (2023) (opens in a new tab)
  154. Vakharia (2025) (opens in a new tab)
  155. Vangsted et al. (2023) (opens in a new tab)
  156. Vemulakonda et al. (2025) (opens in a new tab)
  157. Vujosevic (2025) (opens in a new tab)
  158. Wang and Ying (2021) (opens in a new tab)
  159. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026) (opens in a new tab)
  160. WHO proposed INN List 134 (2025) (opens in a new tab)
  161. WHO recommended INN List 96 (2026) (opens in a new tab)
  162. Williams et al. (2026) (opens in a new tab)
  163. Witkin et al. (2024) (opens in a new tab)
  164. Wong et al. (2014) (opens in a new tab)
  165. Wykoff et al. (2025) (opens in a new tab)
  166. Xin et al. (2018) (opens in a new tab)
  167. Yednock et al. (2022) (opens in a new tab)